EMMA
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.05 | $2M | -$344,000 |
| 2025 Q4 | -0.03 | $4M | $2M |
| 2025 Q3 | -0.03 | $3M | $409,000 |
| 2025 Q2 | -0.02 | $3M | -$3M |
| 2025 Q1 | -0.04 | $2M | $279,000 |
| 2024 Q4 | -0.03 | $3M | $337,000 |
| 2024 Q3 | 0.03 | $5M | $149,000 |
| 2024 Q2 | -0.03 | $5M | -$3M |